PlusNews examines shortages of HIV treatment supplies in Swaziland

NewsGuard 100/100 Score

PlusNews examines Swaziland's national shortages of antiretroviral (ARV) stocks, HIV tests, and lab tests necessary to initiate and manage HIV patients on treatment, and the country's efforts to find funding to prevent stock-outs of these supplies. "Despite several bail-outs this year by international donors, neighboring countries and international NGOs, Swaziland remains in the grips of a months-long shortage of lab reagents needed for CD4 count testing, which measures the immune system's strength and is needed to start patients on ARVs, as well as toxicity testing important in monitoring patients' responses to treatment," the news service writes, noting that funding received in April from PEPFAR will help supply first-line ARVs through April 2012 (11/15). According to BBC News, about 65,000 of the country's 230,000 people living with HIV relies on state hospitals for ARVs (Simelane, 11/15).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Breakthrough study offers hope for an effective HIV cure